Table of Contents
CHAPTER ONE: EXECUTIVE SUMMARY
OVERVIEW
THE NOSOCOMIAL INFECTION
Table 1-1: Frequency of the Most Common Nosocomial Infections
MARKET SCOPE
RESEARCH METHODOLOGY
INDUSTRY CHALLENGES
Table 1-2: Growth Drivers and Inhibitors
TOTAL SIZE AND GROWTH OF THE MARKET
Table 1-3: The Global Market for Hospital Infection Control, 2010-2021
figure 1-1: Global Market for Hospital Infection Control, 2010-2021
ISSUES AND TRENDS AFFECTING MARKET
CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS
OVERVIEW
Introduction to Pathogens
Classification of Antibacterial Organisms
COMMON HOSPITAL (NOSOCOMIAL) INFECTIONS
DESCRIPTION OF INFECTIONS
Acinetobacter Baumannii
Clostridium Difficile
Gastroenteritis
Hospital-Acquired Pneumonia (HAP)
Pseudomonas Aeruginosa
Staphylococcus Aureus/Methicillin-Resistant Staphylococcus Aureus
Stenotrophomonas Maltophilia
Tuberculosis
Urinary Tract Infections
Vancomycin-Resistant Enterococcus
Ventilator-Associated Pneumonia (VAP)
Patient Risk Factors
General Populations at Risk for Infection
Table 2-1: Global Population at Risk for Serious Bacterial Infections, Secondary to Chronic Diseases by Selected Geographical Region (Cancer [newly diagnosed; active treatment], Diabetes, HIV/AIDS, Surgical Procedure, ESRD/Dialysis, Organ Transplants, Cystic Fibrosis; United States, Europe, Other Regions, World)
WORLD DEMOGRAPHICS
figure 2-1: The Global Population, 2005-2050
Table 2-2: Global Population Trends Age 65+, 2000-2050
Assessing the Problem: Nosocomial Infection Statistics
figure 2-2: U.S. Hospital Admissions and Percent of Hospital Acquired Infections (HAIs) (MRSA, C. diff, Others)
figure 2-3: European Union Hospital Admissions and Percent of Hospital Acquired Infections (HAIs) (SSI, Bloodstream, MRSA, Lower RTI, UTI, Others)
Hospital Length of Stay
U.S. GOVERNMENT’S NATIONAL PLAN TO PREVENT HEALTHCARE ASSOCIATED INFECTIONS (HAIS)
STEERING COMMITTEE
EPIDEMIOLOGY AND LABORATORY CAPACITY FOR INFECTIOUS DISEASES
AFFORDABLE CARE ACT (ACA) FUNDING
EMERGING INFECTIONS PROGRAM
Table 2-3: U.S. States ACA HAI Prevention Infrastructure Funding Awards, 2013-2016
THE DEPARTMENT OF HEALTH AND HUMAN SERVICES: 2017 BUDGET HIGHLIGHTS
Table 2-4: U.S. Department of Health & Human Services Fiscal Budget, 2015-2017
NATIONAL HEALTHCARE SAFETY NETWORK
Table 2-5: U.S. Hospital Acquired Infection Standardized Infection Ratio (SIR), 2010-2014
figure 2-4: U.S. Hospital Acquired Infection Standardized Infection Ratio (SIR) 2012 through 2014
HEALTHCARE INFECTION SURVEILLANCE PROCESS
PHARMACEUTICAL MANUFACTURER AND MARKETER TRENDS
Trends in Partnerships and Alliances
Developers Trends
CHAPTER THREE: INFECTION PREVENTION
OVERVIEW
Table 3-1: Methods of Sterilization and Disinfection
MARKET OVERVIEW
Table 3-2: The Global Market for Hospital Infection Prevention Equipment and Consumables (Sterilization/Disinfection), 2010-2021
Healthcare Infection Prevention Market by Geographical Region
Table 3-3: The Global Market for Hospital Infection Prevention (Sterilization/Disinfection) Estimated Products Sales by Primary Geographic Region, 2010-2021 (United States, Europe, Rest of World, Total)
Methods of Transmission
HIGH-RISK FACILITIES OR DEPARTMENTS
Acute Care Hospitals
Long-term Care Facilities
Outpatient Settings
Technology Overview
Table 3-4: Market Value for Infection Prevention Equipment and Related Consumables by Product Type, 2016 (Medical Device/Instrument Sterilization, Wide-Area/Room Sterilization, Medical-grade Disinfection Solutions, Other Products, Total)
Sterilization vs. Disinfection
EQUIPMENT AND SOLUTIONS
Table 3-5: Market Value for Infection Prevention Equipment and Related Consumables by Technology, 2016 (Heat/Steam, Gas/Chemical, Ultrasound, Other, Total)
HEAT/STEAM STERILIZATION
Product Examples
CHEMICAL AND GAS STERILIZATION
Disinfecting Agents and Medical Device Components
Sterilants
Table 3-6: Summary of Advantages and Disadvantages of Chemical Agents Used as Chemical Sterilants or as High-Level Disinfectants
Table 3-7: Comparison of the Characteristics of Selected Chemicals Used as High-Level Disinfectants or Chemical Sterilants
Product Examples
Mid-Level Disinfectants
Table 3-8: Comparison of the Characteristics of Selected Hospital Disinfectants for General Disinfection of Environmental Surfaces
RADIATION STERILIZATION
Product Examples
Table 3-9: Developments, Healthcare Infection Prevention
COMPETITIVE ANALYSIS
Table 3-10: The Global Market for Hospital Infection Prevention (Sterilization/Disinfection), Leading Suppliers’ Shares, Estimates for 2016
CHAPTER FOUR: INFECTION TESTING
OVERVIEW
TOTAL MARKET SIZE AND FORECAST
Table 4-1: The Global Market for Hospital Infection Testing/Diagnostics, 2010-2021
Healthcare Infection Testing Market by Geographical Region
Table 4-2: The Global Market for Hospital Infection Testing/Diagnostics, Estimated Products Sales by Primary Geographic Region, 2010-2021 (United States, Europe, Rest of World, Total)
TESTING FOR NOSOCOMIAL INFECTIONS
Drug-Resistance/Susceptibility Testing
Genotypic Methods
DNA Sequencing
Solid-phase Hybridization Techniques
Microarrays
Real-time Polymerase Chain Reaction Techniques
Phenotypic Methods
Phage-based Assays
Colorimetric Methods
The Nitrate Reductase Assay
Chromogenic Testing
Table 4-3: Market Value for Nosocomial Infection Diagnostics by Class, 2016 (Immunoassays, Microbial Identification / Antimicrobial Sensitivity (ID/AST), Molecular DNA, Total)
SPECIFIC SERIOUS HEALTHCARE INFECTION TESTING
Table 4-4: Tested Samples, Pathogens Isolated by Infection Type (Surgical Site Infection [SSI], Central Line-associated Bloodstream Infections [CLABSI], Catheter-associated Urinary Tract Infections [CAUTI])
Acinetobacter Baumannii
Carbapenem-resistant Enterobacteriaceae
Clostridium Difficile
Product Examples
Hospital-Acquired Pneumonia
Pseudomonas Aeruginosa
Staphylococcus Aureus
Ventilator-Associated Pneumonia
Table 4-5: Significant Approvals for Detecting Serious Healthcare Infections
figure 4-1: HAI Test Approvals in the U.S. by Year and Type, 2000-2016 (Staph/MRSA, C. diff, Others)
figure 4-2: Distribution of Diagnostic Test Approvals with HAI Indications by Pathogen, All Approvals, 2000-2016 (MRSA, C. diff, CRE, VRE, GBS, Others)
Table 4-6: Market Value for Nosocomial Infection Diagnostics by Pathogen Target, 2016 (C. difficile Infections; MRSA Infections;
Enterococcus, vancomycin-resistant; Enterobacteriaceae, carbapenem-resistant; M Tuberculosis; Others; Total)
DEVELOPMENTS
Table 4-7: Ongoing Developments, Healthcare Infection Testing
Table 4-8: Pathogen/Infection Detection Trials by Type
COMPETITIVE ANALYSIS
Table 4-9: The Global Market for Hospital Infection Testing/Diagnostics Leading Suppliers’ Shares Estimates for 2016
CHAPTER FIVE: INFECTION TREATMENT
OVERVIEW
TOTAL MARKET SIZE AND FORECAST
Table 5-1: The Global Market for Hospital Infection Treatment, 2010-2021
Healthcare Infection Treatment Market by Geographical Region
Table 5-2: The Global Market for Hospital Infection Treatment Estimated Products, Sales by Primary Geographic Region, 2010-2021 (United States, Europe, Rest of World, Total)
PRINCIPLES OF ANTI-BACTERIAL THERAPY
Infecting Organism
Antibiotic Sensitivity Testing
Site of Infection
Host Defenses and Organ Function
Antibiotic Pharmacokinetics
Monitoring Therapy
CLASSIFICATIONS OF ANTIBACTERIAL PRODUCTS
Aminoglycosides
Carbapenems
Cephalosporins
Glycopeptides
Macrolides
Penicillins
Quinolones
Sulfonamides
Tetracyclines
MARKET SIZE AND SALES DISTRIBUTION BY ANTIBIOTIC CLASS
Table 5-3: Market Value for Nosocomial Infection Treatments by Class, 2016 (Quinolones, Glycopeptides, ß-lactamase inhibitors, Tetracyclines, Oxazolidinones, Macrolides, Carbapenems, Cephalosporins, Penicillins, Combinations, Others, Total)
Table 5-4: Nosocomial Infection Drug Candidates by Class, 2016 (Quinolones, Glycopeptides, Aminoglycosides, Tetracyclines, Oxazolidinones, Macrolides, Pleuromutilins, Cephalosporins, Fabl inhibitors, Combinations, Others, Total)
INFECTIONS AND DRUG RESISTANCE
Easing Approvals of Antibiotics
Table 5-5: CDER NME NDAs/BLAs Filings and Approvals as of 12/9/15
QUALIFIED INFECTIOUS DISEASE PROGRAM DESIGNATIONS
Causes of Drug Resistance
Drug Resistance in Select Populations
Treatment Guidelines
Table 5-6: Antibiotics with Difficult Penetration
Table 5-7: Market Value for Nosocomial Infection Treatments by Pathogen Target, 2016 (ABSSSI, cUTI, MRSA Infections, HAP/VAP, C. Difficile Infections, Others, Total)
NEW DEVELOPMENTS
Table 5-8: New Developments, Healthcare Infection Treatments, as of December 2016
Table 5-9: Infection Treatments in Development by Phase, as of December 2016
Table 5-10: Infection Treatment Drugs in Development by Route of Administration, as of December 2016
New Developments in Biotherapies for Infection Treatment
COMPETITIVE ANALYSIS
Table 5-11: The Global Market for Hospital Infection Treatment, Leading Suppliers’ Shares, Estimated Share for HAIs for 2016
Table 5-12: Select Treatment Options for Serious Bacterial Infections (Type, Brand, and Manufacturer)
Leading Products
Table 5-13: Annual Sales of Select Antibacterial Products, 2016
CHAPTER SIX: MARKET OPPORTUNITIES FOR HOSPITAL INFECTION CONTROL
MARKET CONSIDERATIONS
MARKET OVERVIEW
Table 6-1: The Global Market for Hospital Infection Control, 2010-2021
figure 6-1: The Global Market for Hospital Infection Control, 2010-2021
figure 6-2: The Global Market for Hospital Infection Control, Estimated Market Share by Segment, 2016 (Treatment, Prevention, Testing)
Healthcare-Acquired Infection Distribution by Setting
figure 6-3: The Global Market for Hospital Infection Control Estimated Market Share by Facility Setting, 2016 (Hospitals, Outpatient
Servicing Centers, Dialysis Centers, Nursing Homes, Community Clinics, Others)
figure 6-4: The Global Market for Hospital Infection Control Estimated Market Share by Hospital Department, 2016 (ICU, Med/Surg, Pediatrics, Others)
Healthcare Infection Control Market by Geographical Region
Table 6-2: The Global Market for Hospital Infection Control, Estimated Products Sales by Primary Geographic Region, 2010-2021 (United States, Europe, Rest of World, Total)
figure 6-5: The Global Market for Hospital Infection Control, Estimated Product Sales by Geographic Region, 2010-2021 (United States, Europe, Rest of World)
figure 6-6: The Global Market for Hospital Infection Control, Estimated Market Share by Geographic Region, 2016 (%) (United States, Europe, Rest of World)
Developed and Emerging Market Analysis
Table 6-3: Developed vs. Emerging Markets
figure 6-7: The Global Market for Hospital Infection Control, Estimated Market Share by Region, 2016 (%) (Developed Europe, Emerging Europe, United States, Rest of World [Japan, India, Canada, Brazil, China, Mexico, Africa, Other Developed, Other Emerging])
CHAPTER SEVEN: COMPANY PROFILES
INTRODUCTION
figure 7-1: Global Markets for HAI by Participant and Segment (Infection Prevention, Infection Diagnostics, Infection Treatment)
3M
Table 7-1: 3M Company Corporate Summary
Company Overview
Company Performance
ABBOTT LABORATORIES
Table 7-2: Abbott Laboratories Corporate Summary
Company Overview
Company Performance
ABBVIE
Table 7-3: AbbVie Corporate Summary
Company Overview
Company Performance
ADVANCED STERILIZATION PRODUCTS
Table 7-4: Advanced Sterilization Products Corporate Summary
Company Overview
Company Performance
ALERE
Table 7-5: Alere Corporate Summary
Company Overview
Company Performance
ASTRAZENECA
Table 7-6: AstraZeneca Corporate Summary
Company Overview
Company Performance
BAYER
Table 7-7: Bayer Corporate Summary
Company Overview
Company Performance
BECTON, DICKINSON AND COMPANY
Table 7-8: Becton, Dickinson Corporate Summary
Company Overview
Company Performance
BELIMED
Table 7-9: Belimed Corporate Summary
Company Overview
Company Performance
BIOMÉRIEUX S.A.
Table 7-10: bioMérieux Corporate Summary
Company Overview
Company Performance
CANTEL MEDICAL CORP.
Table 7-11: Cantel Medical Corporate Summary
Company Overview
Company Performance
DANAHER CORPORATION
Table 7-12: Danaher Corporate Summary
Company Overview
Company Performance
ECOLAB, INC.
Table 7-13: Ecolab Corporate Summary
Company Overview
Company Performance
GETINGE GROUP
Table 7-14: Getinge AB Corporate Summary
Company Overview
Company Performance
GLAXOSMITHKLINE PLC
Table 7-15: GlaxoSmithKline Corporate Summary
Company Overview
Company Performance
MERCK & CO.
Table 7-16: Merck Corporate Summary
Company Overview
Company Performance
PFIZER, INC.
Table 7-17: Pfizer Corporate Summary
Company Overview
Company Performance
ROCHE
Table 7-18: F. Hoffman-La Roche, Ltd. Corporate Summary
Company Overview
Company Performance
SAKURA SEIKI CO., LTD.
Table 7-19: Sakura Seiki Corporate Summary
Company Overview
STERIS PLC
Table 7-20: Steris Corporate Summary
Company Overview
Company Performance
TSO3, INC.
Table 7-21: TSO3 Corporate Summary
Company Overview
Company Performance
APPENDIX: LIST OF PARTICIPANTS
Table A-1: List of Participants
